Focused On-demand Library for Conserved oligomeric Golgi complex subunit 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96MW5

UPID:

COG8_HUMAN

Alternative names:

Component of oligomeric Golgi complex 8

Alternative UPACC:

Q96MW5; Q0VAK2; Q8WVV6; Q9H6F8

Background:

Conserved oligomeric Golgi complex subunit 8, also known as Component of oligomeric Golgi complex 8, plays a pivotal role in maintaining normal Golgi function. This protein is essential for the proper processing and sorting of proteins within the Golgi apparatus, a critical step in cellular homeostasis and protein distribution.

Therapeutic significance:

The protein is directly linked to Congenital disorder of glycosylation 2H, a severe inherited condition marked by a spectrum of symptoms including developmental and neurological issues, stemming from defects in protein N-glycosylation. Understanding the role of Conserved oligomeric Golgi complex subunit 8 could open doors to potential therapeutic strategies for this disorder.